Qualifyze swallows $54M to improve pharmaceutical supply chains [TechCrunch]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: TechCrunch
But too often, the realities can be anything but that. “Officially, GMP stands for ‘Good Manufacturing Practices,'” said Dr. David Schneider, the founder and CEO of Qualifyze . “But people joke that it actually stands for ‘Give Me Paper,' because everything is paper-based in the pharma industry.” The term and the sardonic joke behind it underscore the problem in the pharmaceutical industry, as well as Schneider's efforts to fix it through Qualifyze. The Frankfurt-based startup has built out a network of quality assurance experts plus a large database of suppliers and buyers to help track how a company's supply chain is operating, and how it meets the many fragmented standards that define how the industry works (these include GxP, ESG, ISO, CAPA follow-ups and more). Now, it is announcing a milestone in those efforts: a Series B of $54 million that it will be using to grow, specifically by targeting more business in the U.S. and by expanding its product with more analytics and
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Pulmonary Arterial Hypertension Drugs Market to Grow by USD 2.26 Billion from 2024-2028, as Rising PAH Prevalence Drives Demand with AI Redefining Market Landscape - Technavio [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target lowered by analysts at Barclays PLC from $17.40 to $17.00. They now have an "overweight" rating on the stock.MarketBeat
- Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 11/6/24 - Beat
RDY
Sec Filings
- 11/14/24 - Form 6-K
- 11/12/24 - Form 6-K
- 11/7/24 - Form 6-K
- RDY's page on the SEC website